Related Experiment Video
Updated: Apr 4, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies
James J Morrow1, Chand Khanna2
1Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Abstract:
Osteosarcoma is the most common primary malignancy of bone, typically presenting in the first or second decade of life. Unfortunately, clinical outcomes for osteosarcoma patients have not substantially improved in over 30 years. This stagnation in therapeutic advances is perhaps explained by the genetic, epigenetic, and biological complexities of this rare tumor. In this review we provide a general background on the biology of osteosarcoma and the clinical status quo. We go on to enumerate the genetic and epigenetic defects identified in osteosarcoma. Finally, we discuss ongoing large-scale studies in the field and potential new therapies that are currently under investigation.
Insights
Osteosarcoma, a common bone cancer in young people, has seen little treatment progress due to its complex biology. This review covers osteosarcoma's genetics, epigenetics, and emerging therapies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Osteosarcoma is the most frequent primary bone cancer, predominantly affecting adolescents and young adults.
- Despite its prevalence, clinical outcomes for osteosarcoma patients have remained stagnant for over three decades.
- The limited therapeutic progress is attributed to the intricate genetic, epigenetic, and biological nature of this rare malignancy.
Purpose of the Study:
- To provide a comprehensive overview of osteosarcoma biology and the current clinical landscape.
- To detail the known genetic and epigenetic alterations characteristic of osteosarcoma.
- To discuss ongoing research initiatives and novel therapeutic strategies under investigation for osteosarcoma.
Main Methods:
- Literature review synthesizing current knowledge on osteosarcoma.
- Enumeration of identified genetic and epigenetic defects in osteosarcoma.
- Discussion of findings from large-scale studies and emerging therapeutic targets.
Main Results:
- Osteosarcoma presents significant biological complexity, hindering therapeutic advancements.
- Numerous genetic and epigenetic alterations have been identified, contributing to tumor development and progression.
- Several large-scale studies are underway, exploring new avenues for osteosarcoma treatment.
Conclusions:
- Understanding the complex biology of osteosarcoma is crucial for improving patient outcomes.
- Continued research into genetic and epigenetic factors is essential for developing targeted therapies.
- Emerging therapeutic strategies hold promise for overcoming the current treatment stagnation in osteosarcoma.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
03:03mTOR Signaling and Cancer Progression
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...